Please ensure Javascript is enabled for purposes of website accessibility

Could DexCom Be a Millionaire-Maker Stock?

By Keith Speights - Jul 19, 2020 at 7:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The diabetes-care leader still has tremendous growth prospects.

Winners tend to keep on winning. And make no mistake about it: DexCom (DXCM -0.50%) is a winner.

During its 21 years in business, the medical-device maker has transformed how individuals manage diabetes. DexCom's market cap now stands at close to $40 billion. The company generated nearly $1.5 billion in sales last year. Its profits are growing. Could DexCom even be a millionaire-maker stock? 

Woman with dollar signs next to her head

Image source: Getty Images.

Looking back

There could very well be some investors walking around today who have already become millionaires thanks to buying DexCom stock. The company conducted its initial public offering (IPO) in April 2005. An investment of around $28,250 back then in DexCom would now be worth a little over $1 million. 

Less than a year after its IPO, DexCom launched its first continuous glucose monitoring (CGM) system. In 2007, the company rolled out an even better CGM that could be used for up to seven consecutive days. Over the next few years, DexCom unveiled new generations of CGM technology.

In 2015, the company launched its G5 CGM in September. For the first time, individuals could monitor their glucose levels on their smartphones and other smart devices. That set the stage for DexCom's most impressive innovation to date -- the G6 CGM. Introduced in 2018, the G6 eliminated the need for the inconvenient fingersticks that glucose monitors required previously. 

It's hard to overstate just how important the G6 CGM was to DexCom's fortunes. In the 13 years prior to the launch of the product, its share price increased sixfold. During the two years or so after DexCom won FDA clearance to market the G6, the healthcare stock has soared seven times higher.

Tremendous growth opportunities

Even after its impressive success in the past, DexCom still has tremendous growth opportunities. The company estimates that no more than 40% of Americans with type 1 diabetes currently use CGM systems. Of Americans with intensive type 2 diabetes that requires insulin, only around 15% use CGM systems. That gives DexCom ample room to grow in the important U.S. market. 

But the company's prospects are even greater outside the U.S. More than 460 million adults worldwide have diabetes. It's estimated that only 6% of them are able to live without complications resulting from their condition.

And the opportunities continue to grow. In the U.S. alone, around 1.5 million new cases of diabetes are diagnosed each year.

DexCom hopes to capture more of this expanding market with its G6 CGM. It also plans to launch the G7 CGM next year. This new device will be smaller and less expensive than the G6, which should enable DexCom to gain additional market share. 

Millionaire-maker?

So could DexCom turn investors who buy the stock now into millionaires? It depends on several factors, including your initial investment size and how long you're willing to wait.

If you had $500,000 or more to invest in DexCom, I'm confident that the stock would make you a millionaire within the next few years. Of course, most people don't have that much money to invest, especially in a single stock.

Let's say that you instead have $10,000 that you could use to buy DexCom shares. Your initial investment would need to multiply by 100 times to reach $1 million. Will DexCom be a 100-bagger over the next decade or even the next 20 years? Probably not.

However, DexCom should continue to be a winner for a long time to come. I think it's a great stock to buy right now. But if you want to be a millionaire, you'll probably need to add more winning stocks to your portfolio.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$89.09 (-0.50%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.